BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

...is also a venture partner with Forbion who has held executive positions at portfolio companies Xention Ltd....
BioCentury | Sep 30, 2015
Company News

Management tracks

...CEO. Diagnostic play PlaqueTec Ltd. (Cambridge, U.K.) named Tim Brears CEO. Brears was CEO of Xention Ltd....
BioCentury | Sep 22, 2014
Clinical News

XEN-D0103: Phase II started

...for 28 days in 20 patients with paroxysmal AF who have implanted pacemakers. Last year, Xention...
...and commercialize XEN-D0103 for AF, excluding the U.S. and Japan (see BioCentury, Oct. 7, 2013). Xention Ltd....
BioCentury | Jul 21, 2014
Clinical News

XEN-D0501: Phase IIa started

...prevent cough in patients with chronic obstructive pulmonary disease (COPD). Ario is a spinout of Xention Ltd....
BioCentury | Feb 17, 2014
Clinical News

XEN-D0501: Phase IIa started

...of XEN-D0501 in about 20 patients with chronic idiopathic cough. Ario is a spinout of Xention Ltd....
BioCentury | Dec 16, 2013
Company News

Ario Pharma, Xention pulmonary news

...the transient receptor potential vanilloid 1 ( TRPV1 ; VR1 ) receptor antagonist in 1Q14. Xention...
...a Phase IIa trial (see BioCentury, Jan. 3, 2011). Ario Pharma Ltd. , Cambridge, U.K. Xention Ltd....
BioCentury | Oct 7, 2013
Company News

Xention, Servier deal

...companies will jointly conduct two Phase II trials of the potassium channel Kv1.5 (KCNA5) antagonist. Xention...
...receive upfront and option fees and is eligible for milestones totaling €120 million ($162.3 million). Xention...
...the companies are planning the Phase II trials and the first will start "very soon." Xention...
BioCentury | Oct 3, 2013
Company News

Xention grants Servier option to AF compound, XEN-D0103

...companies will jointly conduct two Phase II trials of the potassium channel Kv1.5 (KCNA5) antagonist. Xention...
...upfront and option fees and is eligible for milestones totaling EUR 120 million ($162.3 million). Xention...
...companies are currently planning the Phase II trials and the first "will start very soon." Xention...
BioCentury | Mar 18, 2013
Emerging Company Profile

Acesion: Accessing SK in AF

...are at least two other programs to improve on the selectivity of marketed AF drugs. Xention Ltd....
...A/S (CSE:NEUR), Ballerup, Denmark Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Teijin Pharma Ltd. , Tokyo, Japan Xention Ltd....
BioCentury | Mar 26, 2012
Clinical News

XEN-D0103: Phase I data

...of 30 subjects showed that XEN-D0103 had no effect on Fridercia's corrected QT interval (QTcF). Xention Ltd....
Items per page:
1 - 10 of 40
BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

...is also a venture partner with Forbion who has held executive positions at portfolio companies Xention Ltd....
BioCentury | Sep 30, 2015
Company News

Management tracks

...CEO. Diagnostic play PlaqueTec Ltd. (Cambridge, U.K.) named Tim Brears CEO. Brears was CEO of Xention Ltd....
BioCentury | Sep 22, 2014
Clinical News

XEN-D0103: Phase II started

...for 28 days in 20 patients with paroxysmal AF who have implanted pacemakers. Last year, Xention...
...and commercialize XEN-D0103 for AF, excluding the U.S. and Japan (see BioCentury, Oct. 7, 2013). Xention Ltd....
BioCentury | Jul 21, 2014
Clinical News

XEN-D0501: Phase IIa started

...prevent cough in patients with chronic obstructive pulmonary disease (COPD). Ario is a spinout of Xention Ltd....
BioCentury | Feb 17, 2014
Clinical News

XEN-D0501: Phase IIa started

...of XEN-D0501 in about 20 patients with chronic idiopathic cough. Ario is a spinout of Xention Ltd....
BioCentury | Dec 16, 2013
Company News

Ario Pharma, Xention pulmonary news

...the transient receptor potential vanilloid 1 ( TRPV1 ; VR1 ) receptor antagonist in 1Q14. Xention...
...a Phase IIa trial (see BioCentury, Jan. 3, 2011). Ario Pharma Ltd. , Cambridge, U.K. Xention Ltd....
BioCentury | Oct 7, 2013
Company News

Xention, Servier deal

...companies will jointly conduct two Phase II trials of the potassium channel Kv1.5 (KCNA5) antagonist. Xention...
...receive upfront and option fees and is eligible for milestones totaling €120 million ($162.3 million). Xention...
...the companies are planning the Phase II trials and the first will start "very soon." Xention...
BioCentury | Oct 3, 2013
Company News

Xention grants Servier option to AF compound, XEN-D0103

...companies will jointly conduct two Phase II trials of the potassium channel Kv1.5 (KCNA5) antagonist. Xention...
...upfront and option fees and is eligible for milestones totaling EUR 120 million ($162.3 million). Xention...
...companies are currently planning the Phase II trials and the first "will start very soon." Xention...
BioCentury | Mar 18, 2013
Emerging Company Profile

Acesion: Accessing SK in AF

...are at least two other programs to improve on the selectivity of marketed AF drugs. Xention Ltd....
...A/S (CSE:NEUR), Ballerup, Denmark Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Teijin Pharma Ltd. , Tokyo, Japan Xention Ltd....
BioCentury | Mar 26, 2012
Clinical News

XEN-D0103: Phase I data

...of 30 subjects showed that XEN-D0103 had no effect on Fridercia's corrected QT interval (QTcF). Xention Ltd....
Items per page:
1 - 10 of 40